FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200375003> ?p ?o ?g. }

• W4200375003 endingPage "182" @default.
• W4200375003 startingPage "175" @default.
• W4200375003 abstract "Lung cancer is one of the most common cancers and an important cause of cancer-related mortality. Recent advances in targeted therapy and immunotherapy have improved outcomes, but these have limited penetration in resource-constrained situations. We report the real-world experience in treating patients with lung cancer in India. A retrospective analysis of baseline characters, treatment and outcomes of patients with lung cancer seen between January 2015 to December 2018 ( n = 302) at our center was carried out. Survival data were censored on July 31, 2019. A total of 302 patients (median age: 57 years [range, 23-84 years]; males [ n = 203; 67.2%]) were registered. Adenocarcinoma was the most common histology ( n = 225, 75%). The testing rate of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation analysis in stage IV adenocarcinoma ( n = 191) was 67% and 63%, respectively. Systemic therapy (chemotherapy/gefitinib) was started after a median of 62 days (range, 1-748) from presentation and 38 days (range, 1-219 days) from diagnosis. The median progression-free survival (PFS) and overall survival (OS) were 4.3 months (95% CI, 3.2-5.4) and 9.0 months (95% CI, 7.6-10.5), respectively in the 141 patient without targetable mutations who started palliative chemotherapy. Of the 58 patients who tested positive for EGFR mutation, 41 (71%) started an EGFR tyrosine kinase inhibitor (TKI), and the median PFS and OS in these patients were 8.5 months (95% CI, 5.6-11.4) and 18.4 months (95% CI, 12.2-24.6), respectively. Only 1 out of 10 patients with stage IV ALK -positive adenocarcinoma was started on ALK inhibitor. On multivariate analysis of OS for patients who started on palliative chemotherapy, response to first-line treatment, long distance from the center, use of second line therapy, and a delay of > 40 days from diagnosis to treatment predicted improved survival. Despite providing free diagnostic and treatment services, there was considerable delay in therapy initiation, and a significant proportion of treatment noninitiation and abandonment. Measures should be taken to understand and address the causes of these issues to realize the benefits of newer therapies The apparent paradox of improved survival in those with long delay in initiation of treatment could be explained based on a less aggressive disease biology." @default.
• W4200375003 created "2021-12-31" @default.
• W4200375003 creator A5004304550 @default.
• W4200375003 creator A5009152399 @default.
• W4200375003 creator A5018712940 @default.
• W4200375003 creator A5034187438 @default.
• W4200375003 creator A5036638907 @default.
• W4200375003 creator A5039337704 @default.
• W4200375003 creator A5047642338 @default.
• W4200375003 creator A5064525438 @default.
• W4200375003 creator A5088957192 @default.
• W4200375003 date "2021-09-01" @default.
• W4200375003 modified "2023-10-12" @default.
• W4200375003 title "Challenges in the Management of Lung Cancer: Real-World Experience from a Tertiary Center in South India" @default.
• W4200375003 cites W1554864276 @default.
• W4200375003 cites W1910874868 @default.
• W4200375003 cites W2009671306 @default.
• W4200375003 cites W2044298512 @default.
• W4200375003 cites W2081135802 @default.
• W4200375003 cites W2081755718 @default.
• W4200375003 cites W2107984617 @default.
• W4200375003 cites W2110697049 @default.
• W4200375003 cites W2121322081 @default.
• W4200375003 cites W2138145250 @default.
• W4200375003 cites W2339303545 @default.
• W4200375003 cites W2505974018 @default.
• W4200375003 cites W2551266350 @default.
• W4200375003 cites W2571492544 @default.
• W4200375003 cites W2579636361 @default.
• W4200375003 cites W2776189506 @default.
• W4200375003 cites W2777258218 @default.
• W4200375003 cites W2780176500 @default.
• W4200375003 cites W2780238395 @default.
• W4200375003 cites W2801979411 @default.
• W4200375003 cites W2889646458 @default.
• W4200375003 cites W2994642443 @default.
• W4200375003 doi "https://doi.org/10.1055/s-0041-1733312" @default.
• W4200375003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34938681" @default.
• W4200375003 hasPublicationYear "2021" @default.
• W4200375003 type Work @default.
• W4200375003 citedByCount "2" @default.
• W4200375003 countsByYear W42003750032022 @default.
• W4200375003 countsByYear W42003750032023 @default.
• W4200375003 crossrefType "journal-article" @default.
• W4200375003 hasAuthorship W4200375003A5004304550 @default.
• W4200375003 hasAuthorship W4200375003A5009152399 @default.
• W4200375003 hasAuthorship W4200375003A5018712940 @default.
• W4200375003 hasAuthorship W4200375003A5034187438 @default.
• W4200375003 hasAuthorship W4200375003A5036638907 @default.
• W4200375003 hasAuthorship W4200375003A5039337704 @default.
• W4200375003 hasAuthorship W4200375003A5047642338 @default.
• W4200375003 hasAuthorship W4200375003A5064525438 @default.
• W4200375003 hasAuthorship W4200375003A5088957192 @default.
• W4200375003 hasBestOaLocation W42003750031 @default.
• W4200375003 hasConcept C117643217 @default.
• W4200375003 hasConcept C121608353 @default.
• W4200375003 hasConcept C126322002 @default.
• W4200375003 hasConcept C141071460 @default.
• W4200375003 hasConcept C143998085 @default.
• W4200375003 hasConcept C2776232967 @default.
• W4200375003 hasConcept C2776256026 @default.
• W4200375003 hasConcept C2776694085 @default.
• W4200375003 hasConcept C2779438470 @default.
• W4200375003 hasConcept C2780580887 @default.
• W4200375003 hasConcept C2781182431 @default.
• W4200375003 hasConcept C71924100 @default.
• W4200375003 hasConcept C90924648 @default.
• W4200375003 hasConceptScore W4200375003C117643217 @default.
• W4200375003 hasConceptScore W4200375003C121608353 @default.
• W4200375003 hasConceptScore W4200375003C126322002 @default.
• W4200375003 hasConceptScore W4200375003C141071460 @default.
• W4200375003 hasConceptScore W4200375003C143998085 @default.
• W4200375003 hasConceptScore W4200375003C2776232967 @default.
• W4200375003 hasConceptScore W4200375003C2776256026 @default.
• W4200375003 hasConceptScore W4200375003C2776694085 @default.
• W4200375003 hasConceptScore W4200375003C2779438470 @default.
• W4200375003 hasConceptScore W4200375003C2780580887 @default.
• W4200375003 hasConceptScore W4200375003C2781182431 @default.
• W4200375003 hasConceptScore W4200375003C71924100 @default.
• W4200375003 hasConceptScore W4200375003C90924648 @default.
• W4200375003 hasIssue "03" @default.
• W4200375003 hasLocation W42003750031 @default.
• W4200375003 hasLocation W42003750032 @default.
• W4200375003 hasLocation W42003750033 @default.
• W4200375003 hasLocation W42003750034 @default.
• W4200375003 hasOpenAccess W4200375003 @default.
• W4200375003 hasPrimaryLocation W42003750031 @default.
• W4200375003 hasRelatedWork W1803443763 @default.
• W4200375003 hasRelatedWork W2015138929 @default.
• W4200375003 hasRelatedWork W2169921827 @default.
• W4200375003 hasRelatedWork W2312235271 @default.
• W4200375003 hasRelatedWork W2358450743 @default.
• W4200375003 hasRelatedWork W2396041313 @default.
• W4200375003 hasRelatedWork W2613088329 @default.
• W4200375003 hasRelatedWork W2802661326 @default.
• W4200375003 hasRelatedWork W2888534976 @default.
• W4200375003 hasRelatedWork W4315780819 @default.
• W4200375003 hasVolume "10" @default.

• next